Safety aspects of gadofosveset in clinical practice – analysis of acute and long-term complications
| Autor: | Peter Leander, Johan Wassélius, Michael Åkesson, Leena Lehti, Per Åkeson, Alaa Alhadad, Gunnar Sterner |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Long term complications medicine.medical_specialty Adolescent Biomedical Engineering Biophysics Contrast Media Gadolinium Risk Assessment Nephrogenic Fibrosing Dermopathy Young Adult Organometallic Compounds medicine Humans Radiology Nuclear Medicine and imaging Child Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry Gadofosveset Magnetic resonance imaging Retrospective cohort study Middle Aged medicine.disease Magnetic Resonance Imaging humanities body regions Clinical Practice Nephrogenic systemic fibrosis Acute Disease Chronic Disease Female Radiology business medicine.drug |
| Zdroj: | Magnetic Resonance Imaging. 32:570-573 |
| ISSN: | 0730-725X |
| DOI: | 10.1016/j.mri.2014.02.012 |
| Popis: | The purpose of this retrospective study was to systematically search for acute adverse reactions and long-term complications in all patients that had been administered gadofosveset at our hospital.We identified 67 gadofosveset administrations during 2006-2009 in 62 patients from 8 to 84years of age. Radiological information system (RIS) and clinical patient records were analyzed for suspected acute adverse reactions and long-term complications including nephrogenic systemic fibrosis (NSF). The gadofosveset doses ranged between 0.024 and 0.060mmol/kg bodyweight with a mean dose of 0.031-mmol/kg bodyweight. Follow-up time of the patients ranged from less than 1year up to 4years with a mean follow-up time of 2.1years.No acute adverse events or technical failures related to the contrast medium were recorded in the RIS. No dermatological and nephrological diseases related to the gadofosveset administration were found in the clinical patient records. Four patients died during follow-up without any apparent relation to the gadofosveset exposure.Based on our clinical material we conclude that gadofosveset is safe for a mixed patient population with no acute adverse events or any indications of long-term complications during the follow-up time up to four years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect